Betta Pharmaceuticals (BETTA HK): Synthetic Expert Call Transcript (31 Aug 2026)
Slowing Core Growth Masked by Non-Recurring Items: While Betta's reported net profit surged by 115.97% in H1 2026, its core Non-GAAP net profit...
94 Views
IPO Databook: Betta Pharmaceuticals (HK) - Aug 2026
Betta Pharmaceuticals is a key player in China's innovative drug industry, evolving into a fully integrated, commercial-stage biopharmaceutical...
105 Views
Primer: Betta Pharmaceuticals (300558 CH) - Aug 2026
Betta Pharmaceuticals is an established player in the Chinese oncology market, driven by its flagship drug, Icotinib (Conmana®), for non-small...
92 Views
Primer: Betta Pharmaceuticals (BETTA HK) - Aug 2026
Betta Pharmaceuticals is a leading Chinese oncology-focused biopharmaceutical company with a proven track record of developing and...
91 Views
Pre-IPO Betta Pharmaceuticals (A/H Listing) - Thoughts on the Pipeline, the Outlook, and Valuation
Betta face challenges due to pipeline with insufficient competitiveness and loss of core talent. Valuation will be lower than peers with more...
214 Views